Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
ID07372196

Left Bundle Branch Pacing Versus Dual-Chamber Cardioverter-Defibrillator Implantation in Patients With Hypertrophic Cardiomyopathy After Myectomy

Led by Meshalkin Research Institute of Pathology of Circulation · Updated on 2026-01-28

30

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and effectiveness of left bundle branch pacing (LBBP) in patients with hypertrophic cardiomyopathy (HCM) who have undergone myectomy surgery and have complete left bundle branch block (LBBB). The study aims to compare the outcomes of implanting a cardioverter-defibrillator (ICD) with LBB pacing versus a traditional dual-chamber ICD in patients at high risk of sudden cardiac death (SCD). This pilot randomized trial will analyze various heart function measures, arrhythmia occurrences, and quality of life over time. Participants are randomly divided into two groups: one receiving a dual-chamber ICD with LBB pacing and the other receiving a standard dual-chamber ICD. The LBB pacing procedure involves implanting electrodes into the interventricular septum near the His bundle to alter heart electrical activation, while the traditional ICD implantation follows standard pacemaker placement techniques. Both groups will undergo ICD programming and assessment at 3, 6, and 12 months after surgery. During the study, researchers will collect demographic and clinical data, including heart function tests, ECG measurements, blood markers like NT-proBNP, and quality of life questionnaires before surgery and 12 months afterward. They will monitor ICD function, complications, heart rhythm episodes, and heart remodeling through echocardiography and ECG at multiple follow-up visits. The study duration includes initial hospitalization and one year of monitoring to evaluate outcomes and safety.

CONDITIONS

Brief Title

Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 18 years and older
  • Diagnosed with hypertrophic cardiomyopathy after myectomy surgery
  • Complete left bundle branch block with a QRS complex greater than 130 ms
  • High risk of sudden cardiac death (6% or higher) based on HCM Risk-SCD
  • Signed informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Absence of left bundle branch block morphology or QRS complex less than 130 ms
  • Presence of baseline complete right bundle branch block
  • Planned heart transplantation or left ventricular assist device implantation within 6 months
  • Intermediate or low risk of sudden cardiac death
  • Heart attack within 3 months prior to study inclusion
  • Acute renal or hepatic failure
  • Acute infectious diseases
  • Presence of mental illness
  • Other illnesses with life expectancy less than one year
  • Patient refusal to participate at any stage

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Day of implantation

Participants will undergo implantation of either a dual-chamber cardioverter-defibrillator with left bundle branch area pacing or a dual-chamber cardioverter-defibrillator without pacing.

1 procedural visit (in-person)

Hospitalization and Immediate Post-operative Care

Duration - Up to several days after implantation

Participants are monitored for complications related to the device implantation procedure and adequate device function during hospitalization.

Approximately 1 hospital stay with monitoring

Follow-up Monitoring

Duration - Up to 12 months after implantation

Participants will be assessed periodically to evaluate device efficiency, heart function, quality of life, and adverse events.

Follow-up visits at 3, 6, and 12 months (in-person)

Trial Site Locations

Total: 1 location

1

Meshalkin Scientific Research Center of the Ministry of Health of Russia

Novosibirsk, Novosibirsk Oblast, Russia, 630055

Actively Recruiting

Loading map...

Research Team

V

Valentina Sergeevna Kirilova, PhD, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Evaluation of Electrocardiographic Data From High-risk Cardi...

Cardiomyopathies

Actively Recruiting

14 locations

Clinical, Instrumental, and Molecular (Circulating and Tissu...

Cardiomyopathies

Actively Recruiting

3 locations

Comparative Effectiveness of Carvedilol Versus Metoprolol Su...

Heart Failure With Reduced Ejection Fraction (HFrEF)

Actively Recruiting

13 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here